1. Home
  2. KOSS vs TLSA Comparison

KOSS vs TLSA Comparison

Compare KOSS & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Koss Corporation

KOSS

Koss Corporation

HOLD

Current Price

$4.03

Market Cap

39.3M

ML Signal

HOLD

Logo Tiziana Life Sciences Ltd.

TLSA

Tiziana Life Sciences Ltd.

HOLD

Current Price

$1.38

Market Cap

155.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KOSS
TLSA
Founded
1953
2013
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Consumer Electronics/Appliances
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
39.3M
155.2M
IPO Year
1994
2017

Fundamental Metrics

Financial Performance
Metric
KOSS
TLSA
Price
$4.03
$1.38
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
19.3K
127.8K
Earning Date
05-07-2026
05-06-2025
Dividend Yield
N/A
N/A
EPS Growth
10.00
N/A
EPS
N/A
N/A
Revenue
$12,624,170.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
2.93
N/A
52 Week Low
$3.61
$0.73
52 Week High
$8.59
$2.60

Technical Indicators

Market Signals
Indicator
KOSS
TLSA
Relative Strength Index (RSI) 46.98 49.41
Support Level N/A $1.27
Resistance Level $5.04 $1.59
Average True Range (ATR) 0.17 0.10
MACD 0.01 0.01
Stochastic Oscillator 65.52 58.00

Price Performance

Historical Comparison
KOSS
TLSA

About KOSS Koss Corporation

Koss Corp is engaged in the design, manufacture, and sale of stereo headphones and related accessory products. It operates in the audio/video industry segment of the home entertainment industry. The company markets a line of headphones, wireless Bluetooth headphones, wireless Bluetooth speakers, computer headsets, telecommunications headsets, and active noise-canceling headphones. The majority of the firm's revenue is derived from sales of stereo headphones. The Company also sells products to distributors for resale to school systems, and directly to other manufacturers for inclusion with their own products.

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications.

Share on Social Networks: